Work

Precision Medicine Is Critical for the Future of Oncology

Year: 2025

Type: article

Abstract: Dr. Christian (Chris) Behrenbruch is the founder and chief executive officer of Telix Pharmaceuticals Ltd. (ASX.TLX, NASDAQ.TLX). He has over 25 y of commercial experience in nuclear medicine and radiology and has founded multiple companies in the field, including Mirada Medical, Adaptix, ImaginAb,

Source: Journal of Nuclear Medicine

DOI: 10.2967/jnumed.125.270966

Authors: Christian Behrenbruch, Ken Herrmann, Johannes Czernin

Institutions: Telix Pharmaceuticals Limited (Australia), Essen University Hospital, University of California, Los Angeles

Language: English

Topic: Medical Imaging Techniques and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4413139489